In a subgroup analysis of patient treated with neoadjuvant therapy, increased TIL concentration was associated with a survival benefit in HER2-positive breast and TNBC patients, but was associated with worse survival in ER-positive/HER2-negative breast cancer patients87. This evidence concerns the gene ERBB2 and breast cancer.